Bio-Techne Corporation’s Stock Price Drops to $69.22, Marking a 3.19% Decrease: Time to Buy or Bail?

Bio-Techne Corporation (TECH)

69.22 USD -2.28 (-3.19%) Volume: 1.14M

Bio-Techne Corporation’s stock price stands at 69.22 USD, witnessing a decline of 3.19% in this trading session with a trading volume of 1.14M. The stock has also experienced a year-to-date (YTD) percentage change of -10.29%, indicating a challenging period for the biotechnology firm in the stock market.

Latest developments on Bio-Techne Corporation

Key events leading up to the current movements in Bio Techne Corp‘s stock price include an average analyst recommendation of “Moderate Buy” for the company’s shares (NASDAQ:TECH). This influential endorsement is likely to have contributed significantly to the recent fluctuations in the Bio-Techne stock market.

Bio-Techne Corporation on Smartkarma

Bio Techne Corp, a healthcare company, has been garnering a lot of attention from investors despite facing challenging macroeconomic conditions. According to a recent report by Baptista Research on Smartkarma, the company reported a 2% decline in organic revenue for the second quarter of the fiscal year 2024. This was mainly due to headwinds such as a cautious biopharma spending environment, a tougher macroeconomic climate in China, and lowered demand from OEM customers. However, Bio Techne’s core portfolio, which has shown an average growth rate of 7% over the last decade, continues to drive the company’s long-term growth potential.

In another report by Baptista Research on Smartkarma, Bio Techne Corporation’s recent financial results were deemed disappointing as the company fell short of Wall Street’s revenue and earnings expectations. This was attributed to challenges faced by the US biopharma funding and evolving macroeconomic conditions in China. However, the report also highlights the company’s strong performance in its growth pillars, including the GMP proteins business, ExoDx prostate, and ProteinSimple franchise. The report also provides a fundamental analysis of the company’s historical financial statements, giving investors valuable insights into Bio Techne’s financial health.

A look at Bio-Techne Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Bio Techne Corp, a company that develops and sells biotechnology products, has received an overall Smartkarma Smart Score of 2.6. This score is determined by five factors: value, dividend, growth, resilience, and momentum. With a score of 3 in both growth and momentum, Bio Techne Corp shows promising signs for the future. This indicates that the company is experiencing positive momentum and has potential for growth. However, with a score of 2 in value, dividend, and resilience, the company may face some challenges in these areas. Overall, the long-term outlook for Bio Techne Corp looks positive based on its Smartkarma Smart Scores.

Based on its Smartkarma Smart Scores, Bio Techne Corp is a biotechnology company that has a promising future. With a score of 3 in both growth and momentum, the company is showing signs of positive momentum and has potential for growth. However, Bio Techne Corp may face some challenges in value, dividend, and resilience, with a score of 2 in each of these areas. Despite these challenges, the company’s overall outlook remains positive. Bio Techne Corp specializes in proteins, cytokines, growth factors, immunoassays, and small molecules, making it a key player in the biotechnology industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma